Ronald M. Cresswell
Corporate Officer/Principal chez University of Michigan
Profil
Dr. Ronald M.
Cresswell is a Member at University of Michigan.
He is on the Board of Directors at NanoBio Corp.
Dr. Cresswell was previously employed as Independent Director by Aastrom Biosciences, Inc., Chief Operating Officer by Laporte Industries Ltd., Chairman & Vice President by Parke, Davis & Co. LLC, Chief Scientific Officer & Senior Vice President by Warner-Lambert Co., and a Principal by Burroughs Wellcome.
He also served on the board at Vasogen, Inc., Allergan, Inc., CuraGen Corp., and Esperion Therapeutics, Inc.
He received his undergraduate degree from the University of Glasgow and a doctorate degree from the University of Glasgow.
Postes actifs de Ronald M. Cresswell
| Sociétés | Poste | Début |
|---|---|---|
| University of Michigan | Corporate Officer/Principal | 31/10/2011 |
Anciens postes connus de Ronald M. Cresswell
| Sociétés | Poste | Fin |
|---|---|---|
| VERICEL CORPORATION | Directeur/Membre du Conseil | 07/05/2014 |
| Burroughs Wellcome | Corporate Officer/Principal | - |
| Parke, Davis & Co. LLC | Président | - |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Directeur Technique/Scientifique/R&D | - |
Laporte Industries Ltd.
 Laporte Industries Ltd. Chemicals: SpecialtyProcess Industries Laporte Industries Ltd. manufactures and distributes specialty chemical products. Laporte Industries is located in London, UK. | Directeur des opérations | - |
Formation de Ronald M. Cresswell
| University of Glasgow | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ESPERION THERAPEUTICS, INC. | Health Technology |
| VERICEL CORPORATION | Health Technology |
| Entreprise privées | 8 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
BlueWillow Biologics, Inc.
 BlueWillow Biologics, Inc. BiotechnologyHealth Technology BlueWillow Biologics, Inc. develops biopharmaceutical products. It offers vaccines targeting respiratory, sexually transmitted, and intranasal immunotherapy for food and respiratory allergies. The company was founded by James R. Baker Jr. and is headquartered in Ann Arbor, MI. | Health Technology |
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Warner-Lambert Co.
Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
Laporte Industries Ltd.
Laporte Industries Ltd. Chemicals: SpecialtyProcess Industries Laporte Industries Ltd. manufactures and distributes specialty chemical products. Laporte Industries is located in London, UK. | Process Industries |
| Burroughs Wellcome | |
| Parke, Davis & Co. LLC |